LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA

Abstract

Even in cases with chronic diffuse ischemic diabetic macular edema, a long-term decrease of central retinal thickness can be observed following repeated intravitreal injections of bevacizumab. In these patients, mean decrease in retinal thickness is aligned with a gain in mean VA. Treatment with bevacizumab at an earlier stage of diabetic macular edema without ischemia may be associated with an even better functional outcome.